1032P - Pharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients

Autor: Bixby, D., Vigil, C.E., Jurcic, J., Cook, R., Sekeres, M.A., Rizzieri, D., Cortes, J., Redner, R., Steensma, D., Roboz, G., Moyo, T., McKeown, M., Waters, N., Stephens, K., di Tomaso, E., Roth, D.A., Stein, E.
Zdroj: In Annals of Oncology September 2017 28 Supplement 5:v367-v367
Databáze: ScienceDirect